Young Adults With Early-onset Obesity Treated With Semaglutide

PHASE4RecruitingINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

June 1, 2022

Primary Completion Date

October 1, 2025

Study Completion Date

April 1, 2026

Conditions
Obesity, Adolescent
Interventions
BEHAVIORAL

TCOC treatment

The TCOC protocol is a chronic care, family-based and multidisciplinary childhood obesity treatment program involving behavior-changing techniques, based on current guidelines for best-practice and authoritative recommendations involving a multidisciplinary tertiary team of health care professionals.

DRUG

Semaglutide 3 mg/ml

Participants will be instructed to initiate at 0.24 mg SC once weekly for 4 weeks, and in 4 week intervals, increase the dose until a dose of 2.4 mg is reached. In case of prolonged side effects the dose may be adjusted to lower than 2.4mg/week.

DRUG

Placebo (Semaglutide 3 mg/ml)

Participants will be instructed to initiate at 0.24 mg SC once weekly for 4 weeks, and in 4 week intervals, increase the dose until a dose of 2.4 mg is reached. In case of prolonged side effects the dose may be adjusted to lower than 2.4mg/week.

Trial Locations (2)

2200

RECRUITING

University of Copenhagen, Department of Biomedical Sciences, Copenhagen

4300

NOT_YET_RECRUITING

Holbæk University Hospital, Holbæk

All Listed Sponsors
collaborator

University of Leeds

OTHER

collaborator

Karolinska Institutet

OTHER

collaborator

Holbaek Sygehus

OTHER

collaborator

Rigshospitalet, Denmark

OTHER

lead

Signe Torekov

OTHER